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Background The risks and benefits of treating
hypertension in individuals older than 80 years are
uncertain. A meta-analysis has suggested that a reduction
in stroke events of 36% may have to be balanced against a
14% increase in total mortality.
Objectives To report the results of the pilot study of the
Hypertension in the Very Elderly Trial (HYVET), which is in
progress to address these issues.
Methods The HYVET-Pilot was a multicentre international
open pilot trial. In 10 European countries, 1283 patients
older than 80 years and with a sustained blood pressure of
160–219/90–109 mmHg were allocated randomly to one
of three treatments: a diuretic-based regimen (usually
bendroflumethiazide; n 26), an angiotensin converting
enzyme inhibitor regimen (usually lisinopril; n 431) or no
treatment (n 426). The procedure permitted doses of the
drug to be titrated and diltiazem slow-release to be added
to active treatment. Target blood pressure was < 150/
80 mmHg and mean follow-up was 13 months.
Results In the combined actively treated groups, the
reduction in stroke events relative hazard rate (RHR) was
0.47 [95% confidence interval (CI) 0.24 to 0.93] and the
reduction in stroke mortality RHR was 0.57 (95% CI 0.25 to
1.32). However, the estimate of total mortality supported
the possibility of excess deaths with active treatment (RHR
1.23, 95% CI 0.75 to 2.01).
Conclusions The preliminary results support the need for
the continuing main HYVET trial. It is possible that
treatment of 1000 patients for 1 year may reduce stroke
events by 19 (nine non-fatal), but may be associated with
20 extra non-stroke deaths. J Hypertens 21:1–9 & 2003
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Introduction
The Hypertension in the Very Elderly Trial (HYVET)
main trial is being conducted to determine the risks
and benefits of the treatment of hypertension in
individuals older than 80 years. As with other long-term
treatments for the prevention of cardiovascular disease,
the risks may change with age. For example, with
anticoagulants there is concern that, in the very elderly,
risks may outweigh benefits [1], and with low-dose
aspirin the reverse may be the case [2].
The pilot trial was performed to test the trial adminis-
tration, obtain a preliminary estimate of the rate of
recruitment, test the techniques of measurement and
recording, determine the safety of the active treatment
and obtain a rough estimate of any treatment effects.
The pilot HYVET trial was an open design that worked
well, but concerns were expressed that only the results
of a double-blind trial conducted to Good Clinical
Practice guidelines would be acceptable in the 21st
century. After completion of the pilot trial, the main
trial was started with an improved design [3]. Without
knowledge of the results of the pilot trial, the Data
Monitoring Committee decided that the results should
be published and placed in the public domain. In the
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event, the results closely support the rationale for the
main trial, by starting to determine the risks and
benefits of treating hypertension in this very elderly
age group.
Methods
In the pilot trial, patients older than 80 years and with
hypertension were allocated randomly but equally to
groups to receive a diuretic-based regimen, an angio-
tensin converting enzyme (ACE)-based regimen or to
no treatment. The drugs administered were bendroflu-
methiazide (bendrofluazide) and lisinopril; to these
active treatments, diltiazem slow-release could be
added to achieve target blood pressure. If one or more
of these drugs was not available to a particular investi-
gator, then a substitute was agreed. The antihyperten-
sive medications were therefore prescribed according to
local practice (usually the National Health System),
and the pilot trial was started before the adoption of
Good Clinical Practice guidelines by the European
Union.
The inclusion criteria were: age more than 80 years,sit-
ting systolic blood pressure (average of four readings)
160–219 mmHg, diastolic blood pressure 95–109
mmHg (later changed to 90–109 mmHg), standing
systolic blood pressure . 140 mmHg (average of two
readings) and provision of informed consent. The
exclusion criteria were serum creatinine . 150 mol/l,
accelerated hypertension, congestive heart failure re-
quiring treatment, inability to stand, cerebral or subar-
achnoid haemorrhage in past 6 months, need for blood
pressure-decreasing treatment because of angina etc.,
the presence of gout, renal artery stenosis, dementia
(abbreviated mental test score , 7/10 [4]) and a condi-
tion expected to limit survival severely.
The procedure has been published in full elsewhere
[5]. The trial recruited individuals from both primary
and secondary care and was of an open design. Two
readings of sitting blood pressure were taken after the
individual had rested for 5 min, in previously treated or
untreated patients, provided treatment had been
stopped for at least 1 week. One month later, the
measurements were repeated again, with no treatment
given during the intervening period. On this occasion
the standing blood pressure was also taken on two
occasions. The diastolic pressure was taken as phase V.
Patients were stratified into four groups on the basis of
sex and age (80–89 years and . 90 years). The unit of
randomization was the individual and the SAS Random
Allocation of Treatments Balanced in Blocks Program
was used to generate the schedule. Restricted random
allocation to groups was used to ensure equal allocation
per group within each centre and allocation to groups
was performed centrally. There were three groups: no
treatment, diuretic-based treatment [usually bendroflu-
methiazide (bendrofluazide) 2.5 mg] and an ACE-inhi-
bitor-based treatment (usually lisinopril 2.5 mg). To
attain target blood pressure in the actively treated
groups, the procedure allowed for the dose of diuretic
or ACE inhibitor to be doubled (step 2), diltiazem
slow-release 120 mg to be added (step 3) and diltiazem
slow-release 240 mg to be added (step 4). The target
blood pressures were a sitting systolic pressure less than
150 mmHg plus a sitting diastolic pressure less than
80 mmHg.
The main endpoints of the trial were stroke events,
total mortality and cardiovascular, cardiac and stroke
mortality. As this was an open study, the randomized
treatment could be continued after a non-fatal event.
Informed written consent was obtained before the
individual was assigned to groups and Ethics Commit-
tee clearance was obtained for all centres.
The pilot trial was supported by the British Heart
Foundation. It was not considered reasonable to ask the
Foundation to bear the costs of treatment, double-
blinding or monitoring of the study. However, although
the pilot trial went smoothly and recruited in excess of
the number of participants originally proposed (500
patients), it was decided that the main trial should be
double-blind, with treatments provided by an industrial
partner and monitoring to Good Clinical Practice. The
pilot trial began in March 1994 and ended in June
1998. The main HYVET trial has now begun [3], with
sponsorship from both The British Heart Foundation
and the Institut de Recherches Internationales Servier.
Statistical considerations
As the trial was a pilot trial with limited numbers and a
short period of follow-up, interim analyses were not
performed. Similarly, although power calculations are
published [3,5], they are not relevant to the pilot trial.
All analyses are presented on an intention-to-treat basis.
Mortality from all causes, cardiovascular and non-
cardiovascular causes, stroke, cardiac and other cardio-
vascular deaths were compared in the three trial groups,
using both the log rank test [6] and the Cox propor-
tional hazards model [7] to adjust for sex, age, previous
myocardial infarction or previous stroke. The effect of
treatment was also determined for fatal plus non-fatal
stroke and the effects in the combined actively treated
groups were also determined in comparison with no
treatment. Database analysis was mostly carried out
using SAS version 8.02.
Results
In this HYVET pilot trial, 1283 patients were allocated
randomly to groups: 1130 (88%) in Bulgaria, 39 (3%) in
Spain, 39 (3%) in Romania, 32 (2.5%) in the UK, 20
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(1.5%) in Poland and smaller numbers in Finland,
Lithuania, Ireland, Greece and Serbia.
Figure 1 presents the flow chart for the trial procedure.
We do not have figures for the total number screened
or followed in the trial run-in period, however, 89
individuals submitted entry forms but were not eligible
for random allocation to groups. Of the 1283 patients
who were assigned to groups, only 27 (2.1%) were lost
to follow-up (had no end-of-trial information). The
average duration of follow-up was 13 months. The
numbers of patient-years of follow-up for those in the
Submitted
for entry  1372
Excluded for not
meeting inclusion criteria  89*
DBP 109 mmHg: n  37
DBP 90 mmHg: n  23
SBP 160 mmHg: n  9
On antihypertensive treatment: n  11
Age 80 years: n  11
Mental test score 7: n  9
Creatinine 150 µmol/l: n  6
Other reasons: n  2
*Patient may have more than one
reason1283
assigned to groups
Diuretic
n  426 (ITT)
Did not receive trial
medication  1
(Died before assignment
to groups)
ACE inhibitor
n  431 (ITT)
Did not receive trial
medication  0
No treatment
n  426 (ITT)
Did not receive trial
medication  2
(Died before assignment
to groups)
Died: n  30 Died: n  27 Died: n  22
Lost to follow-up
n  8
(No information
provided after 6-
month visit  6)
(No information
after withdrawal
for retinal
haemorrhage  1)
(No information
after withdrawal
BP too high  1)
Lost to follow-up
n  7
(No information
provided after 6-
month visit  6)
(No information
after withdrawal
for congestive
heart failure  1)
Lost to follow-up
n  9
(No information
provided after 6-
month visit  9)
386
With information
at end of trial
397
With information
at end of trial
394
With information
at end of trial
Fig. 1
Flow chart for the HYVET-Pilot Trial. SBP, DBP, systolic and diastolic blood pressures; ACE, angiotensin-converting enzyme; ITT, intention-to-treat
analysis; BP, blood pressure.
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diuretic, ACE and no-treatment groups were 473, 493
and 466, respectively.
The average age of the patients was 83.8  3.0 (SD)
years (range 79.5–96.1 years). Three patients were
allocated randomly to groups in error, shortly before
their 80th birthday, but their results are included in the
analysis. Entry systolic blood pressure averaged
181.5  11.3 mmHg (range 160–217 mmHg) and entry
diastolic pressure averaged 99.6  3.4 mmHg (range
90–114 mmHg). One patient with an average diastolic
pressure of 113.8 mmHg was allocated randomly to
groups in error. Average baseline concentration of
creatinine was 102.2  18.5 mol/l and that of potas-
sium 4.32  0.48 mmol/l. The three groups did not
differ in baseline characteristics (Table 1). On average,
the patients were not obese, with an average body mass
index of 25 kg/m2; 48% had been previously treated,
3.0% had had a previous myocardial infarction, 4.5% a
previous stroke, 4.2% were current smokers and 20.7%
drank more than 1 unit of alcohol per day. Table 2
presents the blood pressures and treatments at the end
of the trial. Of the 426 patients allocated randomly to a
diuretic-based treatment, 385 (88.5%) were alive and
provided information at the end of the trial. The
corresponding numbers were 397 (89.8%) for ACE-
based treatment and 394 (90.1%) for no treatment. The
sitting blood pressure had decreased by an average of
30/16 mmHg (systolic/diastolic) with both diuretic- and
ACE-based treatments, and by 7/5 mmHg with no
treatment. The corresponding decreases in standing
blood pressure were 26/15 mmHg, 27/16 mmHg and 3/
4 mmHg for diuretic-based, ACE-based and no treat-
ment, respectively. In the diuretic-based treatment
group, 97% were still taking a diuretic and 16% a
calcium channel blocker. The diuretics were bendro-
flumethiazide (bendrofluazide; 51%), chlorthalidone
(34%) and hydrochlorothiazide (13%). Thirteen percent
of the patients received diltiazem in the ACE-based
treatment group; 96% were still taking an ACE inhibi-
tor, 54% lisinopril and 42% enalapril. In the ‘no
treatment’ group only three individuals (0.8%) were
receiving antihypertensive treatment.
Thirty patients (7.0%) died in the diuretic-based treat-
ment group – a rate of 63.4/1000 patient-years; in the
ACE-based treatment group 27 (6.3%) died – a rate of
54.8/1000 patient-years; in the no-treatment group, 22
(5.2%) died – a rate of 47.2/1000 patient-years.
The deaths were also classified into cardiovascular and
non-cardiovascular deaths, with two deaths from an
unknown cause arbitrarily included as non-cardio-
vascular deaths. There were 23, 22 and 19 cardio-
vascular deaths in the diuretic-, ACE- and no-treatment
groups, respectively, and seven, five and three non-
cardiovascular deaths in the corresponding three
groups. The cardiovascular deaths were further subdi-
vided into stroke (24 deaths), cardiac (29 deaths) and
other cardiovascular (11 deaths). Two of the stroke
deaths were haemorrhagic and the remainder were from
infarction or unspecified. Fatal stroke occurred in six,
seven and 11 patients in the diuretic-, ACE- and no-
treatment groups; non-fatal strokes occurred in 0, five
Table 1 Baseline characteristics of patients in the HYVET-Pilot trial
Diuretic-based
treatment (n ¼ 426)
ACE-based
treatment (n ¼ 431)
No treatment
(n ¼ 426)
Age (years) 83.8  3.3 83.7  3.0 83.8  2.9
79.5–96.1 79.8–93.0 79.6–95.0
Women (%) 62.9 64.0 63.4
Entry BP (mmHg)
Sitting SBP 181.5  11.3 181.9  11.3 181.0  11.5
Sitting DBP 99.6  3.4 99.6  3.3 99.5  3.6
Standing SBP 173.4  12.6 173.6  12.4 173.4  12.3
Standing DBP 98.1  6.1 98.3  5.8 98.1  5.7
Sitting heart rate (beats/min) 76.5  9.5 76  9.7 77.0  9.9
Serum creatinine (mol/l) 102.6  18.0 102.4  18.5 102.3  18.4
Serum sodium (mmol/l) 141.6  4.4 141.8  4.5 142.0  4.1
Serum potassium (mmol/l) 4.33  0.50 4.32  0.48 4.32  0.47
Weight (kg) 67.8  10.5 68.2  11.4 67.9  11.3
Height (cm) 163.8  8.9 163.5  8.7 163.3  8.3
BMI (kg/m2) 25.3  3.4 25.5  3.4 25.4  3.7
Previously treated (%) 46.8 48.3 48.5
Previous MI (%) 2.4 3.0 3.5
Previous stroke (%) 4.2 4.2 5.2
Smokers (%)
Never 89.8 83.7 87.1
Past 7.3 11.2 8.3
Current 2.9 5.1 4.6
Alcohol . 1 unit/day (%) 21.3 22.5 18.4
Values are means  SD, ranges or percentages. ACE, angiotensin-converting enzyme; BP, blood pressure; SBP, DBP,
systolic and diastolic blood pressures; BMI, body mass index; MI, myocardial infarction.
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and seven individuals in the three groups, respectively.
The cardiac deaths were myocardial infarction (15),
other ischaemic heart disease (eight), congestive heart
failure (five) and sudden death (one). The other cardio-
vascular deaths were atherosclerosis (five), pulmonary
embolism (four), hypertension (one) and aortic aneur-
ysm (one). The non-cardiovascular deaths were pneu-
monia or respiratory disease (six), cancer (four),
gastrointestinal haemorrhage (one), unknown (two) and
trauma (two).
Table 3 gives the relative hazard rate (RHR) of having
an event in an active treatment group compared with
the no-treatment group adjusted for age, sex and, as
appropriate, previous myocardial infarction and pre-
vious stroke. Most importantly, the 95% confidence
limits are given and show, as expected for a pilot trial,
that the treatment effects did not usually achieve
statistical significance and that the confidence intervals
(CI) were wide. The effect of being in the diuretic
group was non-significant, with RHRs of 1.31 (95% CI
0.75 to 2.27) for total deaths, 2.09 (95% CI 0.79 to 5.50)
for cardiac deaths and 0.52 (95% CI 0.19 to 1.42) for
stroke deaths. The corresponding results for being in
the ACE group were 1.14 (95% CI 0.65 to 2.02) for
total deaths, 1.40 (95% CI 0.50 to 3.92) for cardiac
deaths and a similar 0.60 (95% CI 0.23 to 1.55) for
stroke deaths. However, for the ‘all stroke events’
analysis, the RHR for fatal plus non-fatal strokes for
both active treatment groups combined decreased to
0.47 (95% CI 0.24 to 0.91; P ¼ 0.02). When results from
the two active treatment groups were combined, total
mortality with active treatment tended to be increased,
with an RHR of 1.23 (95% CI 0.75 to 2.01), and
cardiovascular mortality was 1.13 (95% CI 0.66 to 1.94),
but stroke deaths tended to be reduced: RHR 0.56
(95% CI 0.25 to 1.26). Thus active treatment of 1000
patients for 1 year would save between five and 32
strokes, but tends to produce anything between a
deficit of 12 or an excess of 48 deaths. The point
Table 2 End of trial information (intention-to-treat analysis)
Diuretic-based treatment
(n ¼ 386)
ACE-based treatment
(n ¼ 397)
No treatment
(n ¼ 394)
Blood pressure (mmHg)
Sitting SBP 152  13 151  13 174  11
Sitting DBP 84  7 84  7 95  6
Standing SBP 148  14 147  13 170  12
Standing DPB 83  7 83  7 94  7
Any diuretic 376 (97.4) 2 (0.5) 1 (0.3)
Bendrofluazide
2.5 mg 111 (28.8) 1 (0.3) 1 (0.3)
5.0 mg 81 (21.0) 1 (0.3) 0
. 5.0 mg 1 (0.3) 0 0
Hydrochlorothiazide
12.5 mg 10. (2.6) 0 0
25 mg 21 (5.4) 0 0
50 mg 16 (4.1) 0 0
. 50 mg 4 (1.0) 0 0
Chlorthalidone
25 mg 113 (29.3) 0 0
50 mg 17 (4.4) 0 0
Other diuretics 2 (0.5) 1 (0.3) 0
Any ACE inhibitor 1 (0.3) 381 (96.0) 3 (0.8)
Lisinopril
2.5 mg 1 (0.3) 85 (21.4) 2 (0.5)
5.0 mg 0 126 (31.7) 0
. 5.0 mg 0 3 (0.8) 0
Enalapril
2.5 mg 0 3 (0.8) 0
5.0 mg 0 12 (3.0 0
10 mg 0 84 (21.2) 0
15 mg 0 8 (2.0) 0
20 mg 0 51 (12.8) 0
. 20 mg 0 7 (1.8) 0
Other ACE inhibitors 0 3 (0.8) 0
Calcium channel blockers
Diltiazem 62 (16.1) 51 (12.8) 0
60 mg 9 (2.3) 6 (1.5) 0
120 mg 39 (10.1) 32 (8.1) 0
180–240 mg 14 (3.6) 13 (3.3) 0
No antihypertensive 7 (1.8) 15 (3.8) 391 (99.2)
Values are mean  SD or number (%). ACE, angiotensin-converting enzyme; SBP, DBP, systolic and diastolic
blood pressures. Only one patient received 180 mg.
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estimates suggest a saving of about 19 strokes (nine
non-fatal) for a possible increase of 20 non-stroke
deaths per 1000 patients treated for 1 year.
The effects of age on total mortality and cardiovascular
mortality were highly statistically significant and the
RHRs for 1 year of age ranged from 1.11 for stroke to
1.26 for other (non-stroke, non-cardiac) cardiovascular
disease (Table 3). Male sex consistently (but not
significantly) predicted cardiovascular disease, with
RHRs between 1.41 (stroke) and 2.09 (other cardiac
death). A previous myocardial infarction predicted a
cardiac death (RHR 4.16, 95% CI 1.32 to 13.04), but a
previous stroke did not conclusively predict a stroke
death (RHR 1.57, 95% CI 0.36 to 6.89).
Baseline measurements for creatinine and potassium
are given in Table 1. No patient was withdrawn from
the trial because of renal problems during follow-up.
Serum creatinine concentration was measured in 538
patients within 6 months of random allocation to groups
and in 449 patients after 1 year of follow-up (85% of
those who were available at that time). The mean  SD
‘increase’ in all patients at 6 months from baseline was
1  13 mol/l for the diuretic group, +3  15 mol/l
for the ACE inhibitor group and +1  17 mol/l for the
no-treatment group [analysis of variance (ANOVA);
P ¼ 0.04]. The corresponding mean increases at 12
months were +4  15 mol/l, +4  16 mol/l and +1 
13 mol/l (ANOVA; P ¼ 0.14). The mean changes in
potassium from baseline to 6 months were 0.06 
0.5 mmol/l in the diuretic group, +0.01  0.04 mmol/l in
the ACE inhibitor group and 0.05  0.05 mmol/l in
the no-treatment group (ANOVA; P ¼ 0.34). The corre-
sponding mean changes at 12 months were 0.1  0.04
mmol/l, +0.01  0.05 mmol/l and 0.01  0.4 mmol/l
(ANOVA; P ¼ 0.001). No significant differences changes
were noted for uric acid at 6 or 12 months.
Discussion
Figure 2 presents a comparison of the possible in-
creases in total mortality from active treatment in the
present pilot trial with the results of the meta-analysis
of the result of controlled trials in individuals older
than 80 years reported by Guyeffier et al. [8]. Similarly,
the possible increase in cardiovascular mortality is com-
pared with the results of the meta-analysis, together
with the reduction in fatal plus non-fatal strokes. The
results of the pilot trial agree very well with those of
the meta-analysis. Thus the problem of assessing the
risks and benefits from treatment of mild-to-moderate
hypertension in individuals older than 80 years remains.
The main HYVET trial is designed to provide defini-
tive answers to this problem, and by 7 July 2003 had
already enrolled 1469 patients.
It is of interest that cross-sectional epidemiologicalTa
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studies do not reveal an excess total mortality in hyper-
tensive elderly individuals [9], and a longitudinal study
of blood pressure changes between ages 70 and 90 years
has shown that individuals alive at the age of 93 years
had higher blood pressures at age 90 years than those
who had died. In addition, those with a greater
individual systolic blood pressure at age 79 years than
at age 70 or 75 years also tended to survive to the age
of 90 years [10].
The number of deaths in the pilot trial were insuffi-
cient to suggest any mechanism that could underlie the
increase in mortality. The main trial, if confirming this
problem, is expected to identify the mechanism,
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Fig. 2
Comparison of HYVET-Pilot results with those of the meta-analysis by Gueyffier et al. [7]. Point estimates of the relative hazard rates are given,
together with the 95% confidence intervals. RR, relative risk; ACE, angiotensin-converting enzyme.
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although a previous large trial in the elderly failed to
reach any conclusion. The UK Medical Research
Council trial in the elderly aged 65–74 years [11]
reported both a non-significant decrease in total mortal-
ity and a 26% reduction in cardiovascular deaths in
1081 patients given a diuretic, but non-significant in-
creases in total mortality of 7% and in cardiovascular
mortality of 6% in 1102 patients given a -blocker. A
partial explanation appeared to be that men given
atenolol had a general increase in cancer rate, but
women given atenolol had the lowest cancer rate and
the men tended to have a slight increase in cardio-
vascular mortality. The increase in cancer mortality has
not been confirmed [12].
The main weaknesses of the pilot trial were that it was
an open study and also was not conducted to the
standards of Good Clinical Practice. The problem with
the use of an open design is that both patient and
investigator know the treatment given. This can lead to
bias in several different ways. Investigator bias may
affect what is written on a death certificate: for exam-
ple, if the patient has both a myocardial infarction and
a stroke before death, the investigator may tend to
record a stroke as the underlying cause of death if the
patient is receiving no treatment and blood pressure is
high. The problem was addressed, to some extent, by
coding endpoints without knowledge of the treatment.
However, it is difficult to correct for the initial bias.
Both the investigators’ and the patients’ knowledge of
treatment may affect the withdrawal rates, for example
favouring the removal from the trial of a patient who is
receiving no treatment but has high blood pressure that
approaches but does not exceed a terminating outcome.
In a placebo-controlled double-blind trial, there is al-
ways doubt as to the nature of the treatment, and the
pressure to withdraw because of an adverse event is less.
Similarly, the investigators’ and the patients’ knowledge
will affect the reporting of adverse drug events. In a
double-blind trial, ‘adverse drug events’ are also re-
ported in those receiving placebo, and thus an accurate
estimate of true drug effects may be obtained by
comparing the active and placebo groups. In an open
trial, adverse events are not reported for the placebo
group. Similarly, an individual’s quality of life is im-
proved by their entering a trial, and it is probable that
one component of this effect is receiving treatment. It is
likely that, in an open study, measures of quality of life
when the individual is receiving no treatment will not
improve, and the benefits of treatment may be over-
emphasized. Lastly, it is possible that knowledge of the
treatment will affect the blood pressure that is recorded,
with high measurements being repeated in those receiv-
ing active treatment, but not in the control patients. In
actively treated patients, the second reading is likely to
be lower, exaggerating the effect of treatment.
Nevertheless, it is difficult to see how investigator or
patient bias could affect both the results of the pilot
trial and the meta-analysis – namely a reduction in
stroke events balanced by an increase in total mortality.
However, the main trial is double-blind and conducted
to Good Clinical Practice standards, and it is expected
to report in 2005. Meanwhile, it is possible that
treatment of 1000 patients for 1 year may reduce fatal
plus non-fatal strokes by 19 but be associated with an
excess of 20 non-stroke deaths.
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